Data Insights

Purinostat mesylate by Chengdu Zenitar Biomedical Technology for Refractory Multiple Myeloma: Likelihood of Approval

Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for Refractory Multiple Myeloma....

Likelihood of Approval and Phase Transition Success Rate Model - Purinostat Mesylate in Refractory Multiple Myeloma

Data Insights

Purinostat mesylate by Chengdu Zenitar Biomedical Technology for Relapsed Multiple Myeloma: Likelihood of Approval

Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for Relapsed Multiple Myeloma....

Likelihood of Approval and Phase Transition Success Rate Model - Purinostat Mesylate in Relapsed Multiple Myeloma

Data Insights

Purinostat mesylate by Chengdu Zenitar Biomedical Technology for Unspecified B-Cell Lymphomas: Likelihood of Approval

Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for Unspecified B-Cell Lymphomas....

Data Insights

Purinostat mesylate by Chengdu Zenitar Biomedical Technology for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase II for Anaplastic Large Cell...

Data Insights

Purinostat mesylate by Chengdu Zenitar Biomedical Technology for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma...

Data Insights

Purinostat mesylate by Chengdu Zenitar Biomedical Technology for Cutaneous T-Cell Lymphoma: Likelihood of Approval

Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase II for Cutaneous T-Cell Lymphoma....